GDF15 Antikörper (C-Term) (HRP)

Produktnummer ABIN1043915

Hersteller Produkt- Nr.: 600-403-b07

Der Rabbit Polyclonal Anti-GDF15-Antikörper wurde für WB, ELISA, IHC validiert. Er ist geeignet, GDF15 in Proben von Human, Mouse zu detektieren. Es ist 1 Publikation verfügbar.

Kurzübersicht für GDF15 Antikörper (C-Term) (HRP) (ABIN1043915)

Target: GDF15 (Growth Differentiation Factor 15 (GDF15))

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser GDF15 Antikörper ist konjugiert mit HRP

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Produktdetails anti-GDF15 Antikörper (HRP)

Bindungsspezifität: C-Term

Hersteller Produkt- Nr.: 600-403-b07

Hersteller: Rockland

Verwendungszweck: GDF15 Antibody Peroxidase Conjugated

Kreuzreaktivität (Details): This antibody reacts with the C-terminus of endogenous NAG-1 protein from human and mouse tissues.

Produktmerkmale: Synonyms: rabbit anti-NAG1 antibody peroxidase conjugation, HRP conjugated rabbit anti-NAG1 antibody, NAG 1, NAG-1, GDF15, MIC1, MIC-1, GDF-15, PLAB, PTGFB, nonsteroidal anti-inflammatory drug-activated gene, NSAID-activated gene 1 protein, growth differentiation factor 15, macrophage inhibitory compound 1, Placental bone morphogenetic protein, Prostate differentiation factor

Aufreinigung: Anti-NAG-1 (C-terminal specific) was affinity purified from monospecific antiserum by immunoaffinity chromatography.

Immunogen:

Immunogen: Anti-NAG-1 (C-terminal specific) antibody was prepared by repeated immunizations with a synthetic peptide corresponding to a region near the carboxy terminal end of human NAG-1 protein.  A residue of cysteine was added to facilitate coupling to KLH.

Immunogen Type: Conjugated Peptide

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise:

Immunohistochemistry Dilution: 1:500-1:2,500

Application Note: Anti-NAG1/GDF15 (C-terminal specific) antibody has been tested by ELISA and is suitable for IHC and western blotting of human and mouse NAG-1 protein.  For detection of NAG-1 in human serum, a sandwich ELISA is suggested using this antibody in combination with anti-NAG-1/GDF15 (N-terminal), H variant or D variant specific antibodies.  Specific conditions for reactivity should be optimized by the end user.  Expect bands in Western blots of approximately 14 and 28 kDa in size corresponding to NAG-1 monomer and dimer, respectively, using the appropriate cell lysate or extract.

Western Blot Dilution: 1:1,000-1:5,000

ELISA Dilution: 1:10,000-1:50,000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution:

Reconstitution Volume: 100 μL

Reconstitution Buffer: Restore with deionized water (or equivalent)

Konzentration: 1.07 mg/ml

Buffer:

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Stabilizer: 10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free

Preservative: 0.01 % (w/v) Gentamicin Sulfate. Do NOT add Sodium Azide!

Konservierungsmittel: Gentamicin sulfate

Vorsichtsmaßnahmen: This product contains Gentamicin sulfate: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store vial at 4° C prior to restoration.   For extended storage aliquot contents and freeze at -20° C or below.  Avoid cycles of freezing and thawing.  Centrifuge product if not completely clear after standing at room temperature.  This product is stable for several weeks at 4° C as an undiluted liquid.  Dilute only prior to immediate use. 

Haltbarkeit: 12 months

Referenzen für anti-GDF15 Antikörper (HRP) (ABIN1043915)

Baek, Eling: "Changes in gene expression contribute to cancer prevention by COX inhibitors." in: Progress in lipid research, Vol. 45, Issue 1, pp. 1-16, (2006) (PubMed).

Details zu GDF15

Target: GDF15 (Growth Differentiation Factor 15 (GDF15))

Andere Bezeichnung: GDF15

Hintergrund: Background: Non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. Induced expression of NAG-1 results in stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.

Gen-ID: 9518

UniProt: Q99988

Pathways: SARS-CoV-2 Protein Interaktom